Preclinical research from a top pre-clinical Contract Research Organization in Kiev, Ukraine.
Our company is an independent CRO operating out of the United States that conducts pre-clinical drug testing in state-of-the art, GLP-certified research facilities in Kiev, Ukraine. Our testing sites are sponsored by the UNAMS and Ministry of Health and provide support for commercial development of new drug discoveries as part of their main purpose. Our business was created to provide the top-notch, low-cost services of these facilities to emerging biotech companies in the USA and Europe, thereby providing them with a smart option for promoting development programs quickly and at much lower cost than other commercial Contract Research Organizations. We provide a broad range of preclinical testing including drug safety, acute and chronic toxicity, pharma screening, bioavailability, bioequivalence, and extensive in vitro and in vivo screening for anti-cancer activity.
Our pre-clinical CRO is able to price preclinical testing far below other Contract Research Organizations because we maintain a very low overhead in the USA and conduct all trials in Kiev, UA where labor and laboratory costs are much lower. Our team in the United States is comprised of only of the company principals who deal directly with customers; we have no marketing costs other than our web site, and no main offices, administrative staff or other overhead to increase costs. We have much lower trials conduct prices in Ukraine due to much lower labor rates and are happy to offer our best rates for longer and more intricate preclinical tests where labor is the greatest part of the overall price. Since we utilize the same reliable international suppliers for animal models, reagents and laboratory materials as other CROs, we have no cost advantage on these items and so less overall cost savings for very short-term pre-clinical studies. However, regardless of your trial protocol and length, our goal is to provide our clients the greatest possible value for their investment.